Although the goal of Rhenovia's team is to self-finance its activities, various additional sources are essential to consolidate Rhenovia's platform portfolio and strengthen its competitive advantage.
Rhenovia private funding partners:
www.alsacebusinessangels.com/; and www.sodiv.fr
A virtuous circle
Rhenovia has all the ingredients for an attractive investment:
it addresses urgent medical and societal needs
it targets a huge market in desperate search of new solutions
it already has developed technologies to address medical and pharmaceutical problems
it put in place a business model which facilitates rapid entry on the market
it has potentials for strong growth (with regard to the needs and the demands)
it has exciting development perspectives, as Rhenovia plans to capitalize on its own discoveries with the platforms to develop in the mid-term its own, proprietary pipeline of innovative therapeutics.
Financing Partners: Rhenovia leads RHENEPI, a 2.5 Mio€ program to develop a epilepsy biosimulation platform.
Rhenovia specialized in the optimization of the discovery and development of drugs for Alzheimer's and other diseases of the central and peripheralnervous system, is leading o the RHENEPI, a €2.5 million program awarded by the FUI, the French Fonds Unique Interministeriel in the frame of the 9th Call for Project. This collaborative program obtained the label Cluster of competitiveness Alsace BioValley and Lyon Biopôle.
The goal: to develop an epilepsy biosimulation platform, and obtain experimental validation of in the aim to identify and to practice tests on new antiepileptic drugs and optimize existing drugs.
The program is supported financially by the FUI (11 french ministries including the ministry of Economy, Finances and Industry), OSEO, the French Innovation Organization, the Region Alsace and the cosmopolitan area of Mulhouse, Mulhouse Alsace Agglomération (m2A).
